Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters

Официальное название

Prospective, Observational, Multicentre Study to Confirm the Performance of Molecular Screening for Early Detection of Preeclampsia

Обзор

Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions. Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (\<41%) in compliance with NICE and ACOG guidelines. Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening. The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.

Подробное описание

This multicentre, prospective observational study aims to validate the MaiRa Preeclampsia Test, a molecular screening tool for predicting early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) in the first and second trimesters of pregnancy. The study will evaluate its diagnostic accuracy, including sensitivity, specificity, predictive values, and area under the curve (AUC).

Study Design:

Duration: 40 months

* Recruitment and Sample Collection: 28 months * Sample Analysis: 32 months * Follow-Up: 8 months * Statistical Analysis and Publication: 6 months Participants: 7,473 pregnant women from 12 tertiary hospitals in Spain.

Visits:

* Visit 1 (T1): 9-14 weeks' gestation (first blood sample) * Visit 2 (T2): 15-26 weeks' gestation (second blood sample) * Visit 3 (T3): ≥27 weeks' gestation (third blood sample)

Blood samples will be analyzed using the MaiRa Preeclampsia Test, with results correlated against obstetric outcomes as the gold standard. Data will be documented in an electronic Case Report Form (eCRF). Quality assurance will be maintained via continuous data monitoring and verification.

Вмешательства

• Процедура Peripheral blood collection
  Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.

Первичные конечные точки

• Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE [Срок оценки: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.]

Вторичные конечные точки (2)

• Validation of second-trimester screening (15-26 weeks) for EOPE [Срок оценки: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.]
• Validation of second-trimester screening (15-26 weeks) for LOPE [Срок оценки: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.]

Критерии участия

Критерии включения

• Signed informed consent approved by the Ethics Committee.
• Women ≥18 years of age at consent.
• Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.

Критерии исключения

• Active neoplasm.
• History of organ or bone marrow transplantation.
• Maternal transfusion within 8 weeks before sample collection.
• Evidence of early pregnancy loss at consent.
• Severe, uncontrolled infections.
• Other investigator-assessed risks that could compromise participation or data quality.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Испания · 11 центров

• Hospital General Universitario Dr. Balmis — Alicante
• Hospital de la Santa Creu i Sant Pau — Barcelona
• Hospital Comarcal de Vinaròs — Vinaròs
• Hospital Universitario Puerta del Mar — Cadiz
• Hospital Universitario A Coruña — A Coruña
• Hospital Universitario de Torrejón — Torrejón de Ardoz
• Hospital Clínico Universitario Virgen de la Arrixaca — El Palmar
• Hospital Universitario de Canarias — San Cristóbal de La Laguna
• … и ещё 3 центра

Идентификаторы

NCT: NCT06716242 · IPR-IPR-TG-24-01

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗